-transparent.png){kind=logo}
Eighty-six patients with rheumatoid arthritis treated with sulfasalazine were followed for 5 years, or until treatment was discontinued. At the end of 5 years, there was a 22% probability of successfully continuing treatment. Most adverse effects developed in the first 3 months of treatment. In 38 patients treatment was discontinued because of inefficacy. In 18 of these, a brief period of improvement was followed by clinical relapse. Twenty were regarded as having no useful response to sulfasalazine. The treatment continuation rate of 22% at 5 years is in marked contrast to the pessimistic longterm evaluations of second line drugs that have recently been reported.
Related Publications
E Jones, and
J V Jones, and
J F Woodbury
October 1992,
The Journal of rheumatology,
E Jones, and
J V Jones, and
J F Woodbury
November 1993,
The Journal of rheumatology,
E Jones, and
J V Jones, and
J F Woodbury
May 1991,
Harefuah,
E Jones, and
J V Jones, and
J F Woodbury
January 1989,
Terapevticheskii arkhiv,
E Jones, and
J V Jones, and
J F Woodbury
March 1997,
Arthritis and rheumatism,
E Jones, and
J V Jones, and
J F Woodbury
June 1998,
Clinical orthopaedics and related research,
E Jones, and
J V Jones, and
J F Woodbury
January 2000,
The Cochrane database of systematic reviews,
E Jones, and
J V Jones, and
J F Woodbury
July 1994,
The Journal of rheumatology,
E Jones, and
J V Jones, and
J F Woodbury
June 1987,
The Journal of rheumatology,
E Jones, and
J V Jones, and
J F Woodbury
January 1988,
The Journal of rheumatology,
